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The skin disease erythrokeratoderma variabilis (EKV) has been shown to be associated with mutations in GJB3 and
GJB4 encoding connexin (Cx)31 and Cx30.3, respectively. Gap junctions composed of Cx proteins are intracellular
channels providing a mechanism of synchronized cellular response facilitating metabolic and electronic functions
of the cell. In the skin, Cx31 and Cx30.3 are expressed in the stratum granulosum of the epidermis with a suggested
role in late keratinocyte differentiation. Molecular investigations of GJB3 and GJB4 were performed in ﬁve ped-
igrees and three sporadic cases of EKV. Mutational analyzes revealed disease-associated Cx31 or Cx30.3 mutations
in only three probands of which two were novel mutations and one was a recurrent mutation. These genetic studies
further demonstrate the heterogeneous nature of the erythrokeratodermas as not all individuals that were clinically
diagnosed with EKV harbor Cx31 or Cx30.3 mutations.
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The erythrokeratodermas are a heterogeneous group of
disorders of keratinization. They are usually inherited in an
autosomal dominant fashion, but autosomal recessive
transmission has also been reported. Distinction between
the erythrokeratodermas is usually on clinical grounds and
is not always easy. Erythrokeratoderma variabilis (EKV;
OMIM 133200) usually presents at birth or during infancy. It
is characterized by the coexistence of fixed hyperkeratotic
plaques mainly on the extensor surfaces of the limbs, with
transient erythematous patches, which may be circinate,
geographic, or targetoid in shape. Approximately 50% of
EKV patients have palmoplantar keratoderma (PPK) (Ri-
chard, 2003). The lesions have a predilection for the distal
extremities, buttocks, and trunk. There is considerable in-
tra- and interfamilial variability in severity of the skin dis-
ease, for example, some red patches may last only a few
hours whereas others persist for a few days to a few weeks.
The patches may migrate followed by fine white scaling.
Because of its variable penetrance, the classification of EKV
can often be difficult particularly as it shares clinical features
with other erythrokeratodermas.
Progressive symmetric erythrokeratoderma (PSEK;
OMIM 602036) is one of the less prevalent er-
ythrokeratoderma variants initially described by Gottron
(1922). It is characterized by the development of symmet-
rical plaques on the limbs, buttocks, and face during early
childhood. The plaques progress during childhood and
frequently stabilize during the teenage years (Richard
and Ringpfeil, 2003). It is inherited in an autosomal dom-
inant manner, often with incomplete penetrance. The
main feature distinguishing EKV from PSEK is the variable
erythema and possibly lack of facial lesions in most
cases. Although these erythrokeratodermas are suggested
to be distinct clinical syndromes, in reality there is
considerable phenotypic overlap (van Steensel, 2004).
Moreover, individuals with both a PSEK and EKV pheno-
type have been described in the same family (MacFarlane
et al, 1991).
Other rarer EKV variants described include erythroderma
en cocardes, also known as Degos’ disease (Rajagopalan
et al, 1999), reticulate erythrokeratoderma (Itin et al, 2003),
EKV with erythema gyratum repens-like lesions (Landau
et al, 2002). Saba et al (2005) recently described EKV-like
lesions, ichthyosis, sensorineural hearing loss, peripheral
neuropathy, psychomotor retardation, congenital chronic
diarrhea, and an elevation of very long chain fatty acids in a
French–Canadian pedigree, mapping to chromosome 7q22,
a region containing connexin (Cx)31.1. The identification of
the gene defects associated with this syndrome and the
varer EKV varients would be of interest.
Autosomal dominant EKV was initially linked to chromo-
some 1p34–1p35 where there is a cluster of Cx genes en-
coding the gap junction proteins Cx30.3 (GJB4), Cx31
(GJB3), Cx31.1 (GJB5), and Cx37 (GJA4) (van der Schroeff
et al, 1984; Richard et al, 1997; Macari et al, 2000). Sub-
sequently, pathogenic GJB3 mutations in four families with
Abbreviations: Cx, Connexin; DHPLC, denaturing high perform-
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EKV were identified (Richard et al, 1998), demonstrating a
link between defects in Cx31-associated gap junctions and
aberrant epidermal differentiation and function. To date, six
dominant GJB3 mutations have been identified in eight un-
related EKV families (Richard et al, 1998, 2000; Wilgoss
et al, 1999). All nucleotide changes lead to heterozygous
amino acid substitutions. The mutation L34P in GJB3 was
the first homozygous change providing molecular evidence
for a recessive variant resulting in EKV (Gottfried et al,
2002). A second Cx31 mutation (E100K) has also been de-
scribed associated with recessive EKV (Terrinoni et al, 2004;
Terrinoni and Melino, 2005). GJB3 mutations have been
shown to alter gap junction communication and/or induce
cell death in vitro (Di et al, 2002; Diestel et al, 2002; Rouan
et al, 2003; Terrinoni and Melino, 2005). In transfected ker-
atinocytes, EKV-associated Cx31 mutant proteins had a
cytoplasmic distribution, suggesting that the mutant forms
of this protein will not form normal Cx31 gap junctions be-
tween adjacent cells (Di et al, 2002).
The initial molecular studies of EKV suggested that there
was genetic heterogeneity, as approximately half of the re-
ported families did not have mutations in GJB3. Genetic
studies in a large Israeli–Kurdish family with EKV associated
with erythema gyratum repens, revealed a heterozygous
missense mutation (F137L) in the gene GJB4 encoding
Cx30.3, demonstrating a role for another Cx gene in the
pathogenesis of EKV (Macari et al, 2000). In 13 unrelated
EKV families without mutations in GJB3, six distinct mis-
sense mutations in GJB4 in five families and a sporadic
case of EKV have also been described (Richard et al,
2003a).
In this paper, we describe the clinical phenotypes and
molecular findings in five pedigrees and three sporadic
cases of EKV.
Results
Genetic investigations Affected individuals from five fam-
ilies and three sporadic cases displaying clinical features of
EKV were assessed for disease-causing germline mutations
in the coding sequence of GJB3 and GJB4 encoding Cx31
and Cx30.3, respectively. As with previously described cas-
es of EKV and its variant forms, none of the affected indi-
viduals analyzed in this study had hearing, nail or hair
anomalies. In addition to the dominant pathogenic muta-
tions discovered in this study, several polymorphic se-
quence variants were identified and their allele frequencies
determined in control populations (Table I).
EKV with disease-associated mutation in GJB3 or
GJB4 Three disease-associated mutations were detected
in our EKV cohort. In the family termed EKV1, both affected
individuals (mother and son) had a heterozygous G-to-A
transition at nucleotide 35 in codon 12 of GJB3 (G12D),
changing glycine to aspartic acid (Fig 1A). This mutation has
been previously associated with EKV (Richard et al, 1998).
Both affected family members displayed similar clinical
phenotypes with the classic features of EKV, including sym-
metrical, rugose, hyperkeratotic plaques on the limbs and
trunk with serpiginous borders and more transient, figurate,
erythematous patches and plaques on the chest and neck
(Fig 1B and C). In both cases, dry, scaly skin was observed
in the neonatal period, followed by the development of mi-
grating, erythematous patches or blotches on the trunk and
limbs in the subsequent 4 mo. ‘‘Mauserung-like’’ lesions
were also noted on the extensor aspect of the joints.
In the sporadic case termed EKV2, a novel heterozygous
A-to-T transition at nucleotide 568 was identified in GJB4,
resulting in the amino acid change of methionine to leucine
Table I. GJB3 and GJB4 sequence variants of unknown biological relevance discovered in this study
Nucleotide Amino acid Total allele frequency (%) Afro Caribbean Asian Unknown ethnicity
GJB3
C–T 94 R32W 6/878 (0.68) 2/304 1/80 3/494
G–C 109 V37L 1/878 (0.11) 1/304 0/80 0/494
C–T 357 N119N 51/878 (5.81) 19/304 10/80 22/494
GJB4
C–G 204 F68L 1/746 (0.13) 0/304 0/80 1/362
C–T 207 F69L 2/746 (0.26) 1/304 0/80 1/362
C–T 307 R103C 0/746 (–) 0/304 0/80 0/362
C–G 507 C169W 6/362 (1.66) — — 6/362
C–A 451 R151S 3/362 (0.83) — — 3/362
A–C 611 E204A 3/362 (0.83) — — 3/362
C–T 693 P231P 2/362 (0.55) — — 2/362
G–A 699 T233T 0/362 (–) — — 0/362
C–T 292 R98C 0/362 (–) — — 0/362
C–G 507/Del GTCT C169W/154del4 0/362 (–) — — 0/362
Total number of alleles, allele frequencies, and a breakdown of control population ethnicity are given where known.
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at codon 190 (M190L) of Cx30.3. M190L was not detected
in 878 control chromosomes. On examination, fixed
plaques with elevated edges were observed in the flexures
(Fig 2a) and there was also evidence of mild palmoplantar
desquamation. She also had facial erythema with fine scal-
ing (Fig 2a). Transient, migratory patches were seen on the
lower trunk and arms. Erythematous plaques in the flexures
were reported from the age of 3–4 y.
In the family termed EKV 3, DNA was available from four
family members and was screened for mutations in GJB4
and GJB3. Affected family members 1, 2, and 4 were het-
erozygous for a C-to-T transition at nucleotide 625 in GJB3
(Fig 3) resulting in the substitution of a leucine to phenyl-
alanine at codon 209 of Cx31 (L209F). This change was not
found in 146 control samples from mixed ethnic back-
grounds. In addition, the unaffected mother and one af-
fected family member also harbor a C/T transition at
nucleotide 798 in GJB3 that does not result in an amino
acid substitution or segregate with the disease phenotype.
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Figure 1
GJB3 mutation found in erythrokeratoderma variabilis (EKV)1. (A)
Clinical photographs of the affected mother and son showing classical
features of EKV. (B) The common denaturing high-performance liquid
chromatography (DHPLC) trace for the first fragment of GJB3 PCR
amplified using primers Cx31HPA F and R compared with the DHPLC
trace from the EKV patient. (C). Sequence analysis reveals a G-to-A
transition that substitutes aspartic acid for glycine at codon 12 indi-
cated with an arrow in the patient (E) when compared with the wild-type
sequence (D).
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Figure2
GJB4 mutation M190L in erythrokeratoderma variabilis (EKV)2. (A)
Clinical pictures of the affected patient. (B) The common denaturing
high-performance liquid chromatography (DHPLC) trace for the second
fragment of GJB4 PCR amplified using primers Cx30.3JC1 and
Cx30.3JC7 compared with the DHPLC trace from the EKV patient.
(C) Sequence analysis reveals an A-to-T transition that changes met-
hionine to leucine at codon 190, indicated with an arrow in the patient
(E), when compared with the wild-type sequence (D).
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C/T 798 in GJB3 is likely to be a polymorphism with no
disease association seen in this and other studies (Richard
et al, 2000). The clinical features of this family have already
been described (Perisˇ et al, 1993). Previous work has shown
that Cx mutations associated with both recessive and dom-
inant EKV displayed a characteristic non-membranous lo-
calization when transfected as an EGFP (enhanced green
florescent protein) fusion protein into cell lines. The subcel-
lular localization of (L209F) Cx31-EGFP was analyzed in the
immortalized keratinocyte cell line, NEB1. Like other Cx31
EKV-associated mutant alleles L209F had a primarily cyto-
plasmic localization, characteristic of an in vitro trafficking
defect (Fig 4).
EKV with no mutation or rare polymorphism in GJB3 or
GJB4 The sporadic case termed EKV4 had three genetic
changes in the coding region of GJB4 (Fig 5) of unclear
disease association. A single heterozygous C-to-T substi-
tution at nucleotide 292 in codon 98 (R98C) was identified
changing a conserved arginine to a cysteine in Cx30.3.
R98C was not detected in the control population. In addi-
tion, 154del4 and the more prevalent polymorphism C169W
were also detected (allele frequencies shown in Table I).
Following subcloning and sequencing, R98C and 154del4
were shown to be together on the same GJB4 allele with
C169W on the other. As 154del4 is upstream of R98C, but
before the premature stop codon 55 amino acids down-
stream, this change is unlikely to be pathogenic. It is pos-
sible that this genotype may underlie EKV in this patient, as
C169W/154del4 in GJB4 was not detected in our control
population. We are unable to get wild-type Cx30.3 to traffick
(Di et al, 2005) and functional studies were therefore not
performed with these mutants or M190L (EKV2). The patient
(EKV4) developed symmetrical cutaneous lesions in both
axillae at an age of 2 y. Transient patches of erythema on the
neck and trunk lasting 2–3 wk were described. On exam-
ination, she had symmetrical, lichenified, erythematous
plaques in both axillae and on the neck with well-demar-
cated borders (Fig 5). She had a mild diffuse keratoderma
affecting her palms and a focal keratoderma of the soles.
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Figure 3
GJB3 mutation segregates in erythrokeratoderma variabilis 3 fam-
ily. (A) Clinical pictures of the an affected patient. (B) Pedigree showing
the four available patients for mutation analysis. (C) Sequence analysis
revealed the presence of a C-to-T transition that substitutes leucine 209
with phenylalanine compared with wild-type sequence (D). A second
sequence change, C/T transition at nucleotide 798, was identified that
did not segregate with the disease phenotype (E, F).
Figure4
Transfection of connexin31-EGFP constructs into NEB1 keratin-
ocytes. (A) (WT)Cx31-EGFP was expressed at high levels and was
present at the plasma membrane between two adjacent cells. The large
plaque is characteristic of a gap junction plaque. (B) In contrast,
(L209F)Cx31-EGFP had a primarily cytoplasmic localization with the
protein not seen as a plaque at the boundary between two adjacent
cells.
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Families with no mutations in GBJ3 or GBJ4 genes Al-
though all had clinical features of erythrokeratoderma with a
similar phenotype to EKV1 with or without PPK (see Table
II), three other families and one sporadic case with classical
features of EKV did not harbor a mutation (or rare poly-
morphism(s)) in the GBJ3 or GBJ4 genes.
Histological features The histological features of EKV are
non-specific. Biopsies were available from six of the eight
probands with EKV investigated in this study. Almost all bi-
opsies showed acanthosis of the epidermis with hyper-
keratosis and variable parakeratosis. Hypergranulosis of the
epidermis was noted in both sporadic cases of EKV with a
predominant flexural phenotype (EKV2 and EKV4).
Response to retinoids As retinoic acid has been shown to
downregulate the expression of certain Cx including Cx31
(Grummer et al, 1996), the response of this patient cohort to
retinoids was also assessed and findings summarized in
Table II. Four of six patients treated had a good to excellent
response to oral acitretin. Two of the patients had complete
clearance of their skin disease (indicated by þ þ ), for ex-
ample, the skin disease in EKV8 resolved completely on
acitretin 20 mg daily. The others had some residual skin
disease on treatment, particularly on the legs, for example,
EKV1.
Discussion
We report in this study four distinct point mutations in GJB3
and GJB4 encoding Cx31 and Cx30.3, respectively, three of
which are novel, in two families and two sporadic cases of
EKV. In our patient cohort, one sporadic case and three
families did not have detectable mutations in GJB3 or GJB4
confirming the heterogeneity of this disorder. In addition, no
mutations in these EKV patients were detected in the two
other epidermal disease-associated Cx genes (GJB2 and
GJB6: data not shown). The differential diagnosis of EKV
includes Greither’s disease, keratolytic winter erythema,
non-bullous ichthyosiform erythroderma, and cyclic
ichthyosis with epidermolytic hyperkeratosis (Richard and
Ringpfeil, 2003). None of our cases fitted into these clinical
categories.
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Figure 5
Genetic analysis of erythrokeratoderma variabilis (EKV)4 revealed three changes were present in the coding region of GJB4. (A) T–A cloning
revealed the allelic structure of the three genetic variants with the arrow marking 154del4, the red circle indicating the position of R98C and the blue
circle indicating C169W. (B) Clinical pictures show features of EKV. The three genetic changes were discovered by sequencing analysis. (C) The
novel change R98C and rare polymorphisms (D) 154del4 and (E) C169W as indicated by arrows.
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Our two patients with mutations in GJB3 (EKV1 and 3)
had similar clinical phenotypes with hyperkeratosis which
was most marked on the limbs, transient erythema and
sparing of the central back. A very similar phenotype was
seen in patients/families EKV5-8 although no mutation was
found. Like Richard et al (2003), there was no specific clin-
ical characteristics that differentiated these patients from
patients with mutations in GJB3 or GJB4. It has been pos-
tulated that the GJB4 mutations (e.g., T85P and F137L) as-
sociate with the phenotype of EKV with circinate or gyrate
lesions (Hohl, 2000; Richard et al, 2003). In our study, the
one patient (EKV2) with a bonaﬁde GJB4 mutation (M190L)
showed no clinical signs of this variant form. This patient
had an unusual clinical phenotype with persistent plaques
largely confined to the flexures and transient targetoid ery-
thema on the trunk. Interestingly, a further patient (EKV4)
with rare sequence variants in GJB4 had a similar clinical
phenotype with persistent plaques confined to the flexures.
EKV generally responds well to retinoids. We have noted
that when retinoids are stopped, the initial location for re-
currence of lesions is usually the flexures. These two pa-
tients may therefore represent a more localized, flexural
variant of EKV.
The G12D mutation is in the cytoplasmic NT domain of
Cx31, a highly conserved region that can be expected to
alter the function of Cx31, as the NT domain is thought to be
important in both trafficking of the protein from the Golgi
apparatus to the plasma membrane and voltage gating.
In vitro studies have shown that (G12D)Cx31 protein has a
trafficking defect after transfection into keratinocytes (Di
et al, 2002). The mutation M190L in Cx30.3 occurs within
the fourth transmembrane (TM) domain of GJB4 and is
conserved across at least 16 human Cx. The hydrophobic
methionine residue within the TM domain is likely to play a
crucial role in maintaining the open state lining of the chan-
nel pore (Richard et al, 1998). Unfortunately, we are unable
to get wild-type Cx 30.3 to traffick (Di et al, 2005), so
transfection studies were not performed using this mutant
or the rare sequence variants seen in EKV4. Interestingly,
Plantard et al (2003) recently showed that the Cx30.3 mu-
tation F137L prevents the trafficking of Cx31 and Cx30.3 to
the membrane of HeLa cells and leads to a decrease in
intercellular communication indicating an important inter-
action between Cx31 and Cx30.3 in the formation of gap
junctions. These findings provide a novel explanation for
the similarity in clinical phenotypes between patients with
Cx30.3 and Cx31 mutations, reported in the literature.
The substitution of a leucine at codon 209 of Cx31
(L209F) with the aromatic, highly hydrophobic phenylalanine
is likely to alter the carboxyterminus of Cx31. Functional
analysis of this mutation has revealed that like other Cx31
EKV mutations, expression results in a primarily cytoplas-
mic localization with no gap junction plaques observed be-
tween two adjacent cells. We have previously shown that
the keratinocyte cell line used in this study, NEB1, express-
es low levels of endogneous Cx31 with poor basal dye
transfer. Dye is transferred, however, at a steady rate in
wild-type Cx31-expressing cells suggesting endogenous
protein levels are sufficiently low not to influence the effects
of the exogenous protein (Di et al, 2002). This trafficking
defect of the mutant protein is likely to be a contributing
factor in the disease phenotype of the patients in these
families. Impaired gap junction formation and communica-
tion may have detrimental consequences on epithelial dif-
ferentiation and keratinocyte survival in EKV patients (Di
et al, 2002; Diestel et al, 2002; Rouan et al, 2003).
Other GJB4 rare polymorphisms have been detected
in patients with skin disease. The heterozygous change
R103C in GJB4 was found in a patient with focal PPK and
was not detected in our control population. This genotype is
Table II. Summary of clinical features
Case #
Mutation/
sequence
variant PPK
Generalized
xerosis with
ﬁne scale
Trunk
lesions
Flexural
predominant
Facial
lesions
Transient
erythema
Retinoid/dose/
response Other
EKV1 G12D GBJ3 þ þ þ  þ þ Acitretin/0.25 mg per
kg per d/þ
Mauserung
EKV2 M190L GJB4 þ  þ þ þ þ Acitretin/0.25 mg per
kg per d/þþ
EKV3 L209F GJB3 þ þ / þ /  þ þ NA Circinate
plaques
buttocks
EKV4 R98C/C169W/
154del4 GJB4
þ  þ / þ  þ NA
EKV5 NF þ  þ  þ þ Acitretin/0.25 mg per
kg per d/þ
EKV6 NF  þ þ  þ þ Isotretinoin/0.25 mg
per kg per d/þ /
EKV7 NF þ  þ   þ Acitretin/Dose not
known/
Polycyclic
erythema
buttocks
EKV8 NF   þ þ  þ Acitretin/0.125 mg
per kg per d/þþ
EKV, erythrokeratoderma variabilis.
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unlikely to be the sole cause of the disease phenotype as it
has been reported before in an individual without a derma-
tological condition (Lopez-Bigas et al, 2002). The ho-
mozygous change E204A was observed in a patient with
a PPK and a conductive deafness. This form of deafness is
not likely to be associated with Cx proteins that cause sen-
sorineural hearing impairment. The PPK, however, could be
associated with homozygosity for E204A in GJB4 as the
E204A allele was only seen in the control population (3/362)
in heterozygosity.
In conclusion, this study describes a genetic and clinical
investigation of the erythrokeratodermas that highlights the
importance of Cx mutations in a subset of EKV cases. A
number of EKV cases, however, are clearly because of other
gene mutations. Further genetic studies in large families
with EKV with or without GJB3 or GJB4 mutations are re-
quired to delineate further the molecular and clinical clas-
sification of the erythrokeratodermas.
Materials and Methods
Patients and biologic material We studied 12 affected individu-
als from five pedigrees and three sporadic cases of er-
ythrokeratoderma. Genomic DNA was extracted from the venous
blood of the affected and available unaffected family members
(Nucleon, Manchester, UK). The clinical status of each individual
was established after examination by at least two dermatologists.
Seven of the eight index cases were seen in a single center. Gen-
omic DNA collected from 362 unrelated individuals was used as a
control population. For those controls with known ethnicity, the
frequency of polymorphisms in different ethnic groups was also
determined. Ethical permission for this project was obtained from
the local ethics committee of the East London Clinical Health Au-
thority. Patient consent was given for this study. The study was
conducted according to Declaration of Helsinki Principles.
DNA ampliﬁcation, sequencing, and DHPLC analysis of the
GBJ3 and GBJ4 genes We amplified two overlapping fragments
from genomic DNA that covered the entire coding sequence of
human Cx31 (GJB3) using two primer pairs (Table III). These PCR
products were analyzed by denaturing high-performance liquid
chromatography (DHPLC; Transgenomic, Crewe, UK) and se-
quenced. A similar strategy was employed for the analysis of GJB4
with two overlapping fragments covering the entire coding regions
using the overlapping oligonucleotide primers pairs (Table III). The
DNA fragments were amplified under the following PCR conditions:
35 cycles of 30 s at 941C, 30 s at 621C and 30 s at 721C. The PCR
product was purified using a QIAquick PCR purification kit (QIAgen
Ltd, Crawley, UK) and directly sequenced with v3.1 Big-Dye ter-
minator system and analyzed on a ABI 377 automated sequencer
(PE Applied Biosytems, Warrington, UK). Sequence traces were
analyzed by eye and with Sequence Navigator v1.01 software
(Applied Biosystems, Foster City, California). For heteroduplex for-
mation and DHPLC analysis, all PCR products were heated to 951C
for 5 min followed by cooling at 0.031C per s to a final temper-
ature of 401C. DHPLC was performed using a WAVE DNA Frag-
ment analysis system (Transgenomic). Subcloning of the PCR
product for the GJB4 fragment amplified from the genomic DNA
from EKV9 was performed using the Topo cloning kit (Invitrogen,
Paisley, UK) after gel extraction using the QIAquick gel extraction
kit (QIAgen Ltd). After selection of positive colonies and mini-prep-
arations (QIAgen Ltd), cloned DNA was sequenced with T7 and
SP6 oligonucleotide primers.
Cloning Forward and reverse oligonucleotides were generated
with Sal1 and HindIII restriction sites, respectively, for inframe
cloning into pEGFP-N3. These primers allowed the amplification of
the whole-length gene of interest from normal genomic DNA as
checked against public published sequence data (NM_024009).
Primers used and characterization of this clone has already been
published (Di et al, 2002). Site-directed mutagenesis was carried
out according to manufacturers instructions and as previously de-
scribed for other Cx31 mutations (Stratagene, La Jolla, California)
(Di et al, 2002)). Briefly, an EGFP plasmid containing h(WT)Cx31
was manipulated with oligonucleotide primers containing the de-
sired mutation (L209F)Cx31-EGFP in both the forward and reverse
primer (Table III).
Transfection studies Transfection was performed with the lip-
ofectin-based Transfast reagent according to the manufacturers
instructions (Promega, Southampton, UK). Plasmid DNA at a 1:2
ratio with Transfast was added to NEB1 keratinocytes (Morley et al,
1995) seeded on 13 mM coverslips for an incubation time of 2 h
at 371C. Cells were fixed in 4% paraformaldyhyde 48 h post-
transfection. Coverslips were mounted in antifade containing DAPI
(Vector Labs, Peterborough, UK) to counterstain cell nuclei before
confocal imaging (Zeiss, Orberkochen, Germany).
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